Point72 Asset Management LP recently announced the acquisition of new stake in Bicycle Therapeutics plc (NASDAQ:BCYC). The institutional investor has increased its shareholding in the Healthcare company by 4.71% to 0.4 million shares with purchase of 18000.0 shares. This fresh investment now brings its stake to 2.21% valued currently at $6.3 million. In addition, Victory Capital Management, Inc. raised its holdings by 84238.0 to 0.22 million shares.
With over 24319.0 Bicycle Therapeutics plc (BCYC) shares trading Friday and a closing price of $17.17 on the day, the dollar volume was approximately $0.42 million. The shares have shown a negative weekly performance of -7.51% and its price on 07/24/20 gained nearly 0.35%. Currently, there are 18.00M common shares owned by the public and among those 4.33M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 7 analysts who have offered their price forecasts for BCYC have a consensus price objective of $23.36. The analysts have set the share’s price value over the next 12 months at a high of $30.00 and a low of $17.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Bicycle Therapeutics plc stock is 1.60 for the next 12 months. The average price target is 26.5% above its last price level and an upside to the estimated low will see the stock lose -1.0% over that period. But an upside of 42.77% will see the stock hit the forecast high price target while mean target price for the stock is $23.50.
Insiders at the company have transacted a total of 1 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 1 of these insider trades were purchases, accounting for 71,450 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Bicycle Therapeutics plc are HBM Healthcare Investments, Victory RS Science & Technology F, and USAA Small Cap Stock Fund. HBM Healthcare Investments owns 0.35 million shares of the company’s stock, all valued at over $5.58 million. The company sold 1722.0 shares recently to bring their total holdings to about 1.96% of the shares outstanding. Victory RS Science & Technology F sold 4000.0 shares to see its total holdings shrink to 68270.0 shares valued at over $1.07 million and representing 0.38% of the shares outstanding. USAA Small Cap Stock Fund now owns shares totaling to 0.31% of the shares outstanding.
Shares of Bicycle Therapeutics plc (NASDAQ: BCYC) opened at $18.22, up $1.11 from a prior closing price of $17.11. However, the script later closed the day at $17.17, up 0.35%. The company’s stock has a 5-day price change of -7.51% and 15.16% over the past three months. BCYC shares are trading 82.08% year to date (YTD), with the 12-month market performance up to 103.20% higher. It has a 12-month low price of $6.24 and touched a high of $20.10 over the same period. Currently, 24319.0 shares have been traded, compared to an average intraday trading volume of 47.86K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.17%, 2.77%, and 33.70% respectively.
Institutional ownership of Bicycle Therapeutics plc (NASDAQ: BCYC) shares accounts for 33.10% of the company’s 18.00M shares outstanding. Mutual fund holders own 12.25%, while other institutional holders and individual stakeholders account for 2.67% and — respectively.
It has a market capitalization of $327.60M. The earnings-per-share (ttm) stands at -$1.98. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.00% over the week and 7.20% over the month.
Analysts forecast that Bicycle Therapeutics plc (BCYC) will achieve an EPS of -$0.48 for the current quarter, -$0.53 for the next quarter and -$2.52 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.71 while analysts give the company a high EPS estimate of -$0.27. Comparatively, EPS for the current quarter was -$1.4 a year ago. Earnings per share for the fiscal year are expected to decrease by -124.50%, and -19.40% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 7 brokerage firm advisors rate Bicycle Therapeutics plc (BCYC) as a “Strong Buy” at a consensus score of 1.60. Specifically, 7 Wall Street analysts polled rate the stock as a buy, while 0 of the 7 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the BCYC, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on June 12, 2020, with the firm’s price target at. H.C. Wainwright coverage for the Bicycle Therapeutics plc (BCYC) stock in a research note released on April 17, 2020 offered a Buy rating with a price target of $25. ROTH Capital was of a view on November 14, 2019 that the stock is Buy, while Goldman gave the stock Buy rating on September 11, 2019, issuing a price target of $14. Piper Jaffray on their part issued Overweight rating on June 17, 2019.